PMS27 COST CONSEQUENCE ANALYSIS OF RITUXIMAB TREATMENT FOR RHEUMATOID ARTHRITIS IN ISRAEL
نویسندگان
چکیده
منابع مشابه
Rituximab in the treatment of rheumatoid arthritis.
Rheumatoid arthritis is a chronic, disabling condition and the most common form of inflammatory arthritis affecting approximately 1% of the population. The outlook has improved considerably over the last decade with the recognition that better outcomes accompany early and optimal suppression of synovitis. In some patients, this can be achieved with conventional, oral disease-modifying anti-rheu...
متن کاملRituximab for Rheumatoid Arthritis
Rituximab is a chimeric monoclonal antibody directed at the CD20 molecule on the surfaces of some but not all B cells. It depletes almost all peripheral B cells, but other niches of B cells are variably depleted, including synovium. Its mechanism of action in rheumatoid arthritis (RA) is only partially understood. Rituximab was efficacious in clinical trials of patients with RA, including those...
متن کاملRituximab treatment of refractory rheumatoid arthritis.
OBJECTIVE To review published literature using rituximab for treatment of refractory rheumatoid arthritis (RA). DATA SOURCES An English-language literature search was conducted using MEDLINE (1966-May 2005) and EMBASE (1980-May 2005). References of identified articles were subsequently reviewed for additional data. DATA SYNTHESIS Evidence suggests that B lymphocyte depletion in patients suf...
متن کاملRituximab and its potential for the treatment of rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder which causes deforming joint disease and a spectrum of extraarticular manifestations. Poor disease control may lead to functional impairment and loss of independence. In recent times a prominent role for B cells in the pathogenesis of RA has been suggested. Two major theories have been postulated to explain the role of rheuma...
متن کاملRituximab for the treatment of rheumatoid arthritis: an update
Rituximab is a chimeric monoclonal antibody that targets the CD20 molecule expressed on the surface of B cells. It was first used in the treatment of non-Hodgkin's lymphoma and later approved for the treatment of rheumatoid arthritis (RA) that does not respond adequately to disease-modifying antirheumatic drugs, including the anti-tumor-necrosis-factor (TNF) biologics. Sustained efficacy in RA ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2008
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)66796-4